萎缩顾问:用于干性黄斑变性伴地图样萎缩的临床工具
本研究开发并评估了「萎缩顾问」临床决策工具,整合地图样萎缩进展与个体化寿命估计,以辅助临床医生考虑补体因子抑制剂注射治疗干性黄斑变性伴地图样萎缩。回顾性纳入50例连续患者,中位年龄78岁,基线地图样萎缩距中心凹中位距离792微米,末次随访降至395微米,中位进展速度122微米/年。工具可行,但进展速度和寿命预测存在变异性,需个体化方法。
要点
- 地图样萎缩距中心凹基线中位792微米,末次随访395微米,中位进展122微米/年(范围2-626微米/年)。
- 初始距离与进展速度呈直接关系(P=0.006,R²=0.146)。
- 寿命计算器(康涅狄格大学和萎缩顾问)中位估计分别为11.9年和11.0年,影响4%病例的治疗指导。
核心结论
- 萎缩顾问整合地图样萎缩进展动力学和寿命估计以辅助治疗决策是可行的。
- 进展速度和寿命预测的变异性凸显了个体化方法的必要性。
研究设计与样本
- 回顾性队列研究,纳入2013年5月至2025年6月在Wake Forest附属视网膜诊所就诊的50例连续患者,均为非渗出性年龄相关性黄斑变性继发地图样萎缩。
- 使用ImageJ分析两个或以上时间点的眼底图像,测量中心凹至最近地图样萎缩边缘的距离,以假设垂直视盘直径1800微米进行像素-微米转换。
- 从记录中提取人口学、合并症和矫正视力,使用康涅狄格大学和社会保障局算法计算寿命估计并与观察结局比较。
主要发现
- 中位年龄78岁(IQR:74-82),女性占64%。
- 基线地图样萎缩距中心凹中位距离792微米(IQR:508-1213微米),末次随访降至395微米(IQR:194-702微米)。
- 中位地图样萎缩进展速度122微米/年(范围2-626微米/年),初始距离与进展速度呈直接关系(P=0.006,R²=0.146)。
- 寿命计算器(康涅狄格大学和萎缩顾问)中位估计分别为11.9年和11.0年,影响4%病例的治疗指导。
关键数值与推荐
- 中位年龄78岁(IQR:74-82),女性占64%。
- 基线地图样萎缩距中心凹中位距离792微米(IQR:508-1213微米),末次随访395微米(IQR:194-702微米)。
- 中位进展速度122微米/年(范围2-626微米/年),初始距离与进展速度直接相关(P=0.006,R²=0.146)。
- 寿命计算器中位估计:康涅狄格大学11.9年,萎缩顾问11.0年。
临床怎么用
- 原文未据此给出推荐。
局限性
- 局限性包括测量变异性。
- 局限性包括回顾性设计。
- 未来研究应在更大规模的前瞻性队列中验证该工具。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To develop and evaluate Atrophy Advisor, a clinical decision tool integrating geographic atrophy (GA) progression and personalized lifespan estimates to help clinicians considering complement factor inhibitor injections for dry macular degeneration with GA. DESIGN: Retrospective cohort study. SUBJECTS: Fifty consecutive patients with GA secondary to nonexudative age-related macular degeneration, seen at Wake Forest-affiliated retina clinics from May 2013 to June 2025. METHODS: Fundus images at two or more time points were analyzed using ImageJ to measure the distance from the fovea to the nearest GA edge. Pixel-to-micron conversion was made using an assumed vertical disk diameter of 1800 microns. Demographics, comorbidities, and corrected visual acuities were extracted from records. Lifespan estimates were calculated using University of Connecticut and Social Security Administration algorithms and compared to observed outcomes. MAIN OUTCOME MEASURES: GA edge-to-fovea distance, GA progression rate, corrected visual acuity, and predicted vs observed lifespan. RESULTS: Median age was 78 years (IQR: 74-82); 64% were female. Baseline median GA-to-fovea distance was 792 µm (IQR: 508-1213 µm), declining to 395 µm (IQR: 194-702 µm) at last follow-up. Median GA progression was 122 µm/y (range 2-626 µm/y), with a direct relationship between initial distance and progression rate (P = .006, R² = 0.146). Lifespan calculators (University of Connecticut and Atrophy Advisor) yielded median estimates of 11.9 and 11.0 years, respectively, influencing treatment guidance in 4% of cases. CONCLUSIONS: Atrophy Advisor is feasible for combining GA progression kinetics and lifespan estimates to inform treatment decisions. Variability in progression rates and lifespan predictions highlights the need for personalized approaches. Limitations include measurement variability and retrospective design; future studies should validate the tool in larger, prospective cohorts.
引用
- Kerwin AF, Perlman EM, Browning DJ, et al. Atrophy Advisor: A Clinical Tool for Dry Macular Degeneration With Geographic Atrophy. Am J Ophthalmol. 2025. PMID: 41317829. doi:10.1016/j.ajo.2025.11.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。